Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes

What Was Tested

The paper reports a study of Insulin (regular human) and Insulin Aspart, published as a randomized controlled trial.

Who Took Part

The study group was 595 patients.

PubMed indexes the participants as adults, both men and women.

In this 18-week, 1:1 randomised, open-labelled, parallel trial, 595 patients with Type 1 diabetes mellitus received insulin detemir or NPH insulin in the morning and at bedtime in combination with mealtime insulin aspart or regular human insulin respectively.

How the Study Was Run

The researchers set it up as a randomized, open-label and parallel-group study.

Because people in this Insulin (regular human) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the Insulin (regular human) study did not mask who received what.

The Insulin (regular human) group and the comparison group ran side by side rather than switching.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Diabetes Mellitus, Type 1, Endpoint Determination, Glycated Hemoglobin, Hypoglycemia, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Insulin (regular human) and Insulin Aspart in 595 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2004 (Diabetologia), a journal based in Germany.

More context: the Insulin (regular human) compound page and the Insulin Aspart compound page.